Prognostic Value of Ambulatory Heart Rate Revisited in 6928 Subjects From 6 Populations

Tine W. Hansen, Lutgarde Thijs, José Boggia, Yan Li, Masahiro Kikuya, Kristina Björklund-Bodegård, Tom Richart, Takayoshi Ohkubo, Jørgen Jeppesen, Christian Torp-Pedersen, Lars Lind, Edgardo Sandoya, Yutaka Imai, Jiguang Wang, Hans Ibsen, Eoin O'Brien, Jan A. Staessen and on behalf of the International Database on Populations

Hypertension 2008;52:229-235; originally published online Jun 23, 2008;
DOI: 10.1161/HYPERTENSIONAHA.108.113191

Hypertension is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 75254
Copyright © 2008 American Heart Association. All rights reserved. Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/cgi/content/full/52/2/229

Subscriptions: Information about subscribing to Hypertension is online at http://hyper.ahajournals.org/subscriptions/

Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. Fax: 410-528-8550. E-mail: journalpermissions@lww.com

Reprints: Information about reprints can be found online at http://www.lww.com/reprints
Heart Rate and Cardiovascular Risk

Prognostic Value of Ambulatory Heart Rate Revisited in 6928 Subjects From 6 Populations

Tine W. Hansen, Lutgarde Thijs, José Boggia, Yan Li, Masahiro Kikuya, Kristina Björklund-Bodegård, Tom Richart, Takayoshi Ohkubo, Jørgen Jeppesen, Christian Torp-Pedersen, Lars Lind, Edgardo Sandoya, Yutaka Imai, Jiguang Wang, Hans Ibsen, Eoin O’Brien, Jan A. Staessen, on behalf of the International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators

Abstract—The evidence relating mortality and morbidity to heart rate remains inconsistent. We performed 24-hour ambulatory blood pressure monitoring in 6928 subjects (not on β-blockers; mean age: 56.2 years; 46.5% women) enrolled in prospective population studies in Denmark, Belgium, Japan, Sweden, Uruguay, and China. We computed standardized hazard ratios for heart rate, while stratifying for cohort, and adjusting for blood pressure and other cardiovascular risk factors. Over 9.6 years (median), 850, 325, and 493 deaths accrued for total, cardiovascular, and noncardiovascular mortality, respectively. The incidence of fatal combined with nonfatal end points was 805, 363, 439, and 324 for cardiovascular, stroke, cardiac, and coronary events, respectively. Twenty-four-hour heart rate predicted total (hazard ratio: 1.15) and noncardiovascular (hazard ratio: 1.18) mortality but not cardiovascular mortality (hazard ratio: 1.11) or any of the fatal combined with nonfatal events (hazard ratio: ≤1.02). Daytime heart rate did not predict mortality (hazard ratio: ≤1.11) or any fatal combined with nonfatal event (hazard ratio: ≤0.96). Nighttime heart rate predicted all of the mortality outcomes (hazard ratio: ≥1.15) but none of the fatal combined with nonfatal events (hazard ratio: ≤1.11). The night:day heart rate ratio predicted total (hazard ratio: 1.14) and noncardiovascular mortality (hazard ratio: 1.12) and all of the fatal combined with nonfatal events (hazard ratio: ≥1.15) with the exception of stroke (hazard ratio: 1.06). Sensitivity analyses, in which we stratified by risk factors or from which we excluded 1 cohort at a time or the events occurring within 2 years of enrollment, showed consistent results. In the general population, heart rate predicts total and noncardiovascular mortality. With the exception of the night:day heart rate ratio, heart rate did not add to the risk stratification for fatal combined with nonfatal cardiovascular events. Thus, heart rate adds little to the prediction of cardiovascular risk. (Hypertension. 2008;52:229-235.)

Key Words: heart rate ■ mortality ■ cardiovascular disease ■ risk factors ■ epidemiology

Studies in hypertensive patients1–4 or populations5–12 suggested that heart rate, either measured at rest1,2,4–7,9–12 or by ambulatory blood pressure monitoring,1–3 might be a predictor of total,1–12 cardiovascular,4,6,7,9,11 or noncardiovascular mortality.1,5,6 However, as highlighted by a 2006 consensus document,13 the evidence relating outcome to heart rate remains incomplete and lacks consistency. Most researchers reported only on fatal outcomes.3,9,11,12,14 Other investigators failed to demonstrate an independent association between total,1,5,15 or cardiovascular,2,5,15 mortality and resting1,5,15 or ambulatory heart rate,1,2,4,14,15 or found that adjustment for blood pressure removed the association.8 A further issue complicating the interpretation of the published evidence is that the relation between heart rate and cardiovascular mortality or death from coronary heart disease might be more pronounced in men than in women or in middle-aged compared with older subjects.5,7,8 To address these issues, the 2006 consensus document13 advocated further research. An international consortium recently constructed a database of prospective population stud-
ies with the goal to advance research on the stratification of risk by ambulatory blood pressure measurement. In keeping with the 2006 consensus document, we used this international database to investigate in more detail the relation between fatal and nonfatal outcomes and heart rate on 24-hour, daytime, and nighttime measurement in >6900 subjects randomly recruited from 6 populations.

Methods

Study Population

As described in detail elsewhere, we constructed the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes (IDACO). Studies were eligible for inclusion if they involved a random population sample, if baseline information on ambulatory blood pressure and cardiovascular risk factors was available, and if the subsequent follow-up included fatal and nonfatal outcomes.

For the current analysis, we considered 2311 residents from Copenhagen, Denmark; 2542 subjects recruited from Noorderkempen, Belgium; 1535 inhabitants of Ohasama, Japan; 1221 older men from the population of Uppsala, Sweden; 1859 subjects recruited from Montevideo, Uruguay; and 360 villagers from JingNing County, China. All of the studies included in IDACO received ethical approval. Participants gave informed written consent. Of the 9828 subjects, we excluded 2900 (29.6%) because they were ≤18 years old at the moment of enrollment (n=15), because their conventional blood pressure had not been measured (n=217), because they were on treatment with β-blockers (n=538), or because their daytime (n=224) or nighttime (n=1906) blood pressure and heart rate had not been measured or were averages of <10 or 5 readings, respectively. Thus, the number of subjects statistically analyzed totaled 6928. We also analyzed risk related to the conventional heart rate in 5742 subjects (82.9%) for whom this information was available.

Blood Pressure and Heart Rate

Trained observers measured the conventional blood pressure with a mercury sphygmomanometer or with validated auscultatory devices, using the appropriate cuff size, with the subjects in the sitting or supine position and counted heart rate over ≥15 seconds. The conventional blood pressure was the average of 2 consecutive readings. We defined hypertension as a conventional blood pressure of ≥140 mm Hg systolic or 90 mm Hg diastolic or as use of antihypertensive drugs. We initiated the portable blood pressure monitor to obtain blood pressure and heart rate readings at 30-minute intervals throughout the whole day or at intervals ranging from 15 to 30 minutes during daytime and from 30 to 60 minutes at night.

While accounting for the daily pattern of activities of the participants, we defined daytime as the interval ranging from 10 AM to 8 PM in Europeans and South Americans and from 8 AM to 6 PM in Asians. The corresponding nighttime intervals ranged from midnight to 6 AM and from 10 PM to 4 AM, respectively. We weighted the within-subject means of the ambulatory heart rate and blood pressure by the time interval between readings. In addition, we computed the night:day ratio of heart rate and systolic blood pressure.

Other Measurements

In all of the cohorts, we administered a questionnaire to obtain baseline information on each subject’s medical history, intake of medications, and smoking and drinking habits. Body mass index was body weight in kilograms divided by height in meters squared. Serum cholesterol and blood glucose were determined by automated enzymatic methods. Diabetes mellitus was a self-reported diagnosis; a fasting or random blood glucose level of ≥7.0 mmol/L (126 mg/dL) or 11.1 mmol/L (200 mg/dL); respectively; or use of antidiabetic drugs.

Ascertainment of Events

We ascertained vital status and the incidence of fatal and nonfatal diseases from the appropriate sources in each country, as described in previous publications. Fatal and nonfatal stroke did not include transient ischemic attacks. Coronary events encompassed death from ischemic heart disease, sudden death, nonfatal myocardial infarction, and coronary revascularization. Cardiac events were composed of coronary end points and fatal and nonfatal heart failure. The composite cardiovascular end point included all of the aforementioned end points plus cardiovascular mortality. In all of the outcome analyses, we only considered the first event within each category.

Statistical Methods

For database management and statistical analysis, we used SAS 9.1.3 (SAS Institute). For comparison of means and proportions, we applied the t test for large samples and the χ² statistic, respectively. After stratification for cohort and sex, we imputed missing values of body mass index (n=10) and total serum cholesterol (n=48) from the regression slope on age. In subjects with unknown smoking status (n=30) or drinking habits (n=368 among Swedish men and 154 among the other cohorts), we set the design variable to the cohort- and the-specific mean of the codes (0 and 1). Statistical significance was an α-level of 0.05 on 2-sided tests.

We used Cox regression to compute standardized hazard ratios. We checked the proportional hazards assumption by the Kolmogorov-type supremum test, as implemented in the PROC PHREG procedure of the SAS package and by testing the interaction terms between follow-up duration and the variable of interest. We first plotted incidence rates by fifths of the distributions of the daytime and nighttime heart rate while standardizing by the direct method for cohort, sex, and age (≥40, 40 to 60, and ≥60 years, respectively). We stratified Cox models for the cohort. We adjusted hazard ratios for age (treated as a continuous variable), systolic blood pressure, body mass index, smoking and drinking, serum total cholesterol, history of cardiovascular disease, diabetes mellitus, and treatment with antihypertensive drugs. Cox models, including the night:day ratio of heart rate, were additionally adjusted for the night:day ratio of systolic blood pressure. We tested heterogeneity in the hazard ratios across subgroups by introducing the appropriate interaction term in the Cox model.

Results

Baseline Characteristics

The study population consisted of 3993 Europeans (57.6%), 1553 Asians (22.4%), and 1382 South Americans (19.9%). The 6928 participants included 3219 women (46.5%) and 2494 patients with hypertension on conventional blood pressure measurement (36.0%), of whom 693 (27.8%) were taking blood pressure–lowering drugs, not including β-blockers. Mean ± SD age was 56.2 ± 14.0 years. The conventional blood pressure averaged 131.3 ± 20.5 mm Hg systolic and 79.7 ± 11.5 mm Hg diastolic. Heart rate averaged 72.6 ± 9.1 bpm over 24 hours and 78.2 ± 10.4 and 63.9 ± 9.5 bpm during daytime and nighttime, respectively. At enrollment, 2057 participants (29.7%) were current smokers, and 3306 (47.7%) reported intake of alcohol. Conventional heart rate was available in 5742 subjects, averaging 70.4 ± 11.6 bpm.

Table 1 shows the baseline characteristics by quartiles of the 24-hour heart rate. Across the quartiles, all of the characteristics were significantly different (P<0.05), with the exception for 24-hour systolic blood pressure (P=0.68), nighttime systolic blood pressure (P=0.33), and the proportion of patients with diabetes mellitus (P=0.70) or a history of cardiovascular disease (P=0.78). Participants with a
coronary revascularization. Of the coronary revascularization
cases, 24 sudden deaths, 16 fatal and 121 nonfatal cases of
myocardial infarction, 19 deaths from ischemic heart dis-
ease, and 45 cases of surgical or percutaneous
procedures, 16 occurred in Noorderkempen, 1 in Copen-
13642a-gen, and 28 in Montevideo.

Incidence of Events
In the overall study population, the median follow-up was 9.6
years (fifth to 95th percentile interval: 2.5 to 13.8 years).
Across cohorts, median follow-up ranged from 2.5 years
(fifth to 95th percentile interval: 2.3 to 2.6 years) in JingNing
to 13.2 years (fifth to 95th percentile interval: 0.9 to 15.8
years) in Noorderkempen. During 64 400 person-years of
follow-up, 850 participants died (13.2 per 1000 person-
years), and 805 experienced a fatal or nonfatal cardiovascular
24-hour systolic blood pressure (P=0.68), nighttime systolic
blood pressure (P=0.33), and the prevalence of diabetes mellitus (P=0.70) and cardiovascular disorder (P=0.78).

Risk Associated With Heart Rate and
Blood Pressure
The Figure shows the cohort-, sex-, and age-standardized
rates of mortality and fatal combined with nonfatal outcomes
across quintiles of the daytime and nighttime heart rates. The
multivariate-adjusted hazard ratios associated with 1-SD
increase in the conventional and ambulatory heart rates
appear in Table 2 for fatal end points, as well as for fatal
combined with nonfatal cardiovascular events.

Mortality
In adjusted models, nighttime heart rate predicted total,
cardiovascular, and noncardiovascular mortality, whereas
daytime heart rate did not predict any of these fatal outcomes.
The conventional heart rate, the 24-hour heart rate, and the
daylight heart rate did not predict any of these fatal outcomes.

higher heart rate were younger and more likely to be female
and smokers compared with those with lower heart rate
(Table 1).

Incidence of Events
In the overall study population, the median follow-up was 9.6
years (fifth to 95th percentile interval: 2.5 to 13.8 years).
Across cohorts, median follow-up ranged from 2.5 years
(fifth to 95th percentile interval: 2.3 to 2.6 years) in JingNing
to 13.2 years (fifth to 95th percentile interval: 0.9 to 15.8
years) in Noorderkempen. During 64 400 person-years of
follow-up, 850 participants died (13.2 per 1000 person-
years), and 805 experienced a fatal or nonfatal cardiovascular
complication (13.0 per 1000 person-years). Mortality included
325 cardiovascular and 493 noncardiovascular deaths
and 32 deaths from unknown cause (Table 2). Considering
cause-specific first cardiovascular events, the incidence of
fatal and nonfatal stroke amounted to 49 and 314, respec-
tively. Cardiac events consisted of 116 fatal and 323 nonfatal
events, including 57 fatal and 157 nonfatal cases of acute
myocardial infarction, 19 deaths from ischemic heart dis-
ese, 24 sudden deaths, 16 fatal and 121 nonfatal cases of
heart failure, and 45 cases of surgical or percutaneous
coronary revascularization. Of the coronary revascularization

Table 1. Baseline Characteristics of Participants by Quartiles of 24-Hour Heart Rate

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Limits, bpm</th>
<th>≤66.3</th>
<th>&gt;66.3 to ≤72.2</th>
<th>&gt;72.2 to ≤78.4</th>
<th>&gt;78.4</th>
</tr>
</thead>
<tbody>
<tr>
<td>All subjects in category, n (%)</td>
<td>n=1732</td>
<td>n=1732</td>
<td>n=1732</td>
<td>n=1732</td>
<td></td>
</tr>
<tr>
<td>European</td>
<td>1083 (62.5)</td>
<td>1008 (58.2)</td>
<td>980 (56.6)</td>
<td>922 (53.2)</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>592 (30.5)</td>
<td>484 (27.9)</td>
<td>361 (20.8)</td>
<td>179 (10.3)</td>
<td></td>
</tr>
<tr>
<td>South American</td>
<td>120 (6.9)</td>
<td>240 (13.9)</td>
<td>391 (22.6)</td>
<td>631 (36.4)</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>580 (33.5)</td>
<td>811 (46.8)</td>
<td>883 (51.0)</td>
<td>945 (54.6)</td>
<td></td>
</tr>
<tr>
<td>Antihypertensive treatment*</td>
<td>351 (20.3)</td>
<td>264 (15.3)</td>
<td>149 (14.4)</td>
<td>236 (13.6)</td>
<td></td>
</tr>
<tr>
<td>Smokers</td>
<td>366 (21.2)</td>
<td>454 (26.4)</td>
<td>563 (32.6)</td>
<td>674 (39.0)</td>
<td></td>
</tr>
<tr>
<td>Using alcohol</td>
<td>875 (57.7)</td>
<td>834 (52.2)</td>
<td>883 (50.8)</td>
<td>764 (46.3)</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>122 (7.0)</td>
<td>124 (7.2)</td>
<td>113 (6.5)</td>
<td>109 (6.3)</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular disorder</td>
<td>125 (7.2)</td>
<td>124 (7.2)</td>
<td>112 (6.5)</td>
<td>125 (7.2)</td>
<td></td>
</tr>
<tr>
<td>Age, mean±SD, y</td>
<td>60.2±13.2</td>
<td>57.5±13.0</td>
<td>55.1±13.9</td>
<td>51.8±14.2</td>
<td></td>
</tr>
<tr>
<td>Body mass index, mean±SD, kg/m²</td>
<td>25.1±5.6</td>
<td>25.3±3.9</td>
<td>25.5±4.1</td>
<td>26.0±4.7</td>
<td></td>
</tr>
<tr>
<td>Conventional heart rate, mean±SD, bpm†</td>
<td>61.2±6.6</td>
<td>67.0±8.1</td>
<td>71.9±8.9</td>
<td>79.5±11.4</td>
<td></td>
</tr>
<tr>
<td>Ambulatory measurements, mean±SD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daytime heart rate, bpm</td>
<td>66.1±5.4</td>
<td>75.0±3.9</td>
<td>81.1±4.2</td>
<td>90.7±6.8</td>
<td></td>
</tr>
<tr>
<td>Nighttime heart rate, bpm</td>
<td>54.2±5.1</td>
<td>60.7±4.8</td>
<td>66.1±5.2</td>
<td>74.6±7.9</td>
<td></td>
</tr>
<tr>
<td>24-h systolic, mm Hg</td>
<td>125.2±13.8</td>
<td>124.5±14.5</td>
<td>124.2±14.3</td>
<td>123.7±15.0</td>
<td></td>
</tr>
<tr>
<td>24-h diastolic, mm Hg</td>
<td>72.1±7.8</td>
<td>73.2±8.4</td>
<td>74.4±8.2</td>
<td>75.9±9.1</td>
<td></td>
</tr>
<tr>
<td>Daytime systolic, mm Hg</td>
<td>131.7±14.8</td>
<td>131.3±15.8</td>
<td>130.7±15.3</td>
<td>130.0±15.9</td>
<td></td>
</tr>
<tr>
<td>Daytime diastolic, mm Hg</td>
<td>76.8±8.6</td>
<td>78.2±9.1</td>
<td>79.6±9.2</td>
<td>81.2±9.8</td>
<td></td>
</tr>
<tr>
<td>Nighttime systolic, mm Hg</td>
<td>113.8±15.0</td>
<td>112.6±14.9</td>
<td>112.4±15.2</td>
<td>112.3±16.0</td>
<td></td>
</tr>
<tr>
<td>Nighttime diastolic, mm Hg</td>
<td>63.8±8.6</td>
<td>64.4±9.1</td>
<td>65.1±8.7</td>
<td>66.3±10.1</td>
<td></td>
</tr>
<tr>
<td>Serum cholesterol, mmol/L</td>
<td>5.6±1.1</td>
<td>5.7±1.2</td>
<td>5.7±1.1</td>
<td>5.8±1.2</td>
<td></td>
</tr>
</tbody>
</table>

†Data were available in 5742 subjects.

Trend tests across the 4 groups were significant (P<0.05) except for 24-hour systolic blood pressure (P=0.68), nighttime systolic blood pressure (P=0.33), and the prevalence of diabetes mellitus (P=0.70) and cardiovascular disorder (P=0.78).
and treatment with antihypertensive drugs. The analyses of the night:day ratio of heart rate were additionally adjusted for night:day ratio of systolic blood pressure.

measured over the same interval as heart rate, body mass index, smoking and drinking, serum total cholesterol, history of cardiovascular disease, diabetes mellitus, and treatment with antihypertensive drugs. The analyses of the night:day ratio of heart rate were additionally adjusted for night:day ratio of systolic blood pressure.

P
stroke (as well as cardiac and coronary, events but not fatal and nonfatal

blood pressure, while stratifying for cohort and adjusting for covariates.

Fatal and Nonfatal Cardiovascular Events
With adjustments applied as before (Table 2), the night:day ratio of heart rate ($P<0.005$) predicted cardiovascular, as well as cardiac and coronary, events but not fatal and nonfatal stroke ($P=0.23$). However, heart rate did not predict

$P=0.06$) any of the fatal combined with nonfatal outcomes, irrespective of whether it was measured in the clinic, over 24 hours, or over daytime or nighttime (Table 2).

Sensitivity Analyses
In sensitivity analyses, we considered total and noncardiovascular mortality in relation to the 24-hour and nighttime heart rate and to the night:day ratio of heart rate. We stratified the study population according to sex, median age (60 years), history of cardiovascular disease, smoking and drinking habits, treatment status, and the presence or absence of hypertension on conventional blood pressure measurement. Table 3 lists the characteristics, for which we noticed a significant difference between the strata for $\geq 1$ outcome. For all of the other stratification factors, the interaction terms with the 24-hour ($P=0.06$) or nighttime ($P=0.13$) heart rate or with the night:day ratio of heart rate ($P=0.13$) were not statistically significant. Furthermore, sensitivity analyses from which we excluded 1 cohort at a time produced results consistent with those in the overall study population (Table S1). Moreover, the addition of an interaction term between ethnicity (Asian, Latin American, or European) and any measure of heart rate did not improve the fit of the Cox models ($P=0.09$).

Calcium channel blockers can influence heart rate. A sensitivity analysis from which we excluded patients treated with $\beta$-blockers, calcium channel blockers, or both produced consistent results (Table S2). The prevalence of a history of cardiovascular disease was 6.8% and 26.0% in participants not or on $\beta$-blockade at enrollment ($P<0.001$). However, including 538 patients on $\beta$-blockers did not materially alter our results (Table S3).

Finally, our results remained consistent when we analyzed ambulated heart rate standardized to a body height of 165 cm (median of the whole study population), when we added a squared term of ambulated heart rate to the regression models, when we substituted systolic blood pressure in our models by diastolic blood pressure or mean arterial pressure, or when we added conventional heart rate to models already including ambulatory heart rate. Our results also did not

$P=0.05$, $\dagger P=0.01$, and $\ddagger P<0.001$.

Table 2. Adjusted Standardized Hazard Ratios Relating Heart Rate to Different Outcomes

<table>
<thead>
<tr>
<th>Label</th>
<th>Total</th>
<th>Cardiovascular</th>
<th>Noncardiovascular</th>
<th>Combined Cardiovascular Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events, n (%)</td>
<td>697 (12.1)</td>
<td>277 (4.8)</td>
<td>389 (6.8)</td>
<td>693 (12.1)</td>
</tr>
<tr>
<td>Conventional</td>
<td>1.14 (1.04 to 1.25)</td>
<td>1.14 (0.99 to 1.32)</td>
<td>1.17 (1.03 to 1.32)*</td>
<td>1.03 (0.94 to 1.12)</td>
</tr>
<tr>
<td>Events, n (%)</td>
<td>850 (12.3)</td>
<td>325 (4.7)</td>
<td>493 (7.1)</td>
<td>805 (11.6)</td>
</tr>
<tr>
<td>24-h</td>
<td>1.15 (1.06 to 1.25)</td>
<td>1.11 (0.97 to 1.26)</td>
<td>1.18 (1.06 to 1.31)$</td>
<td>$</td>
</tr>
<tr>
<td>Daytime</td>
<td>1.00 (0.99 to 1.16)</td>
<td>1.05 (0.92 to 1.19)</td>
<td>1.11 (1.00 to 1.23)$</td>
<td>$</td>
</tr>
<tr>
<td>Nighttime</td>
<td>1.20 (1.11 to 1.30)$</td>
<td>$</td>
<td>1.15 (1.01 to 1.31)*</td>
<td>1.22 (1.10 to 1.36)$</td>
</tr>
<tr>
<td>Night/day ratio</td>
<td>1.14 (1.05 to 1.23)$</td>
<td>$</td>
<td>1.12 (0.99 to 1.27)</td>
<td>1.12 (1.01 to 1.24)$</td>
</tr>
</tbody>
</table>

Values are standardized hazard ratios (95% CIs), which express the risk per SD increase in the heart rate, unless otherwise specified. Heart rate SDs were 11.6, 9.1, 10.4, and 9.5 bpm for conventional, 24-hour, daytime, and nighttime, respectively. The SD of night:day heart rate ratio was 0.09. The cause of death was unknown in 32 cases. Conventional heart rate was available in 5742 subjects. All of the hazard ratios were stratified by cohort and adjusted for age, systolic blood pressure, while stratifying for cohort and adjusting for age, systolic blood pressure, diastolic blood pressure or mean arterial pressure, and treatment with antihypertensive drugs. The analyses of the night:day ratio of heart rate were additionally adjusted for night:day ratio of systolic blood pressure.

In sensitivity analyses, we considered total and noncardiovascular mortality in relation to the 24-hour and nighttime heart rate and to the night:day ratio of heart rate. We stratified the study population according to sex, median age (60 years), history of cardiovascular disease, smoking and drinking habits, treatment status, and the presence or absence of hypertension on conventional blood pressure measurement. Table 3 lists the characteristics, for which we noticed a significant difference between the strata for $\geq 1$ outcome. For all of the other stratification factors, the interaction terms with the 24-hour ($P=0.06$) or nighttime ($P=0.13$) heart rate or with the night:day ratio of heart rate ($P=0.13$) were not statistically significant. Furthermore, sensitivity analyses from which we excluded 1 cohort at a time produced results consistent with those in the overall study population (Table S1). Moreover, the addition of an interaction term between ethnicity (Asian, Latin American, or European) and any measure of heart rate did not improve the fit of the Cox models ($P=0.09$).

Calcium channel blockers can influence heart rate. A sensitivity analysis from which we excluded patients treated with $\beta$-blockers, calcium channel blockers, or both produced consistent results (Table S2). The prevalence of a history of cardiovascular disease was 6.8% and 26.0% in participants not or on $\beta$-blockade at enrollment ($P<0.001$). However, including 538 patients on $\beta$-blockers did not materially alter our results (Table S3).

Finally, our results remained consistent when we analyzed ambulated heart rate standardized to a body height of 165 cm (median of the whole study population), when we added a squared term of ambulated heart rate to the regression models, when we substituted systolic blood pressure in our models by diastolic blood pressure or mean arterial pressure, or when we added conventional heart rate to models already including ambulatory heart rate. Our results also did not
change when we excluded subjects who experienced an event within 2 years of enrollment (Table S4).

**Discussion**

The key finding of our study was that a higher heart rate significantly and independently predicted total mortality. This effect was mainly mediated by the association of heart rate with noncardiovascular mortality rather than cardiovascular mortality. Nighttime heart rate predicted cardiovascular mortality with a 14% higher risk per SD increase in the cardiac frequency (≈10 bpm). Neither daytime nor nighttime heart rate predicted any of the fatal combined with nonfatal cardiovascular mortality. However, in analyses adjusted for blood pressure and other risk factors, each 10% decrease in the nocturnal slowing of heart rate was associated with higher total mortality (hazard ratio: 1.30; 95% CI: 1.02 to 1.65) but not with cardiovascular events.2 Ben-Dov et al3 analyzed total mortality in 3957 referred patients across deciles of the awake and asleep heart rate and of the nocturnal decrease in heart rate. He demonstrated that total mortality increased with higher sleeping heart rate (P=0.02) and decreased with more nocturnal fall in heart rate (P<0.001) but was unrelated to the awake heart rate (P=0.50). Two population studies, the Ohasama Study14 and the Pressioni Arteriose Monitorate e Loro Associazioni findings were equally negative for both total and cardiovascular mortality.15 In contrast, home heart rate was a significant predictor of cardiovascular mortality in 1780 Japanese subjects included in the Ohasama Study.34

The present study has potential limitations. First, the IDACO database is currently composed of 6 population-based cohorts from 3 continents,18–23 but our results might not be generally applicable, in particular to Africans of black ancestry or African Americans. For this reason, we are presently collecting outcome results in additional cohorts, although to our knowledge no prospective population data are available in black subjects.35–37 Second, the 6 populations differed in anthropometric characteristics and lifestyle, and conventional heart rate was only available in 82.9% of our studied 1942 hypertensive patients enrolled in the Progetto Ipertensione Umbria Monitoraggio Ambulatoriale. The 24-hour heart rate was unrelated to total mortality or combined fatal and nonfatal cardiovascular events. However, in analyses adjusted for blood pressure and other risk factors, each 10% decrease in the nocturnal slowing of heart rate was associated with higher total mortality (hazard ratio: 1.30; 95% CI: 1.02 to 1.65) but not with cardiovascular events.2 Ben-Dov et al3 analyzed total mortality in 3957 referred patients across deciles of the awake and asleep heart rate and of the nocturnal decrease in heart rate. He demonstrated that total mortality increased with higher sleeping heart rate (P=0.02) and decreased with more nocturnal fall in heart rate (P<0.001) but was unrelated to the awake heart rate (P=0.50). Two population studies, the Ohasama Study14 and the Pressioni Arteriose Monitorate e Loro Associazioni findings were equally negative for both total and cardiovascular mortality.15 In contrast, home heart rate was a significant predictor of cardiovascular mortality in 1780 Japanese subjects included in the Ohasama Study.34

The present study has potential limitations. First, the IDACO database is currently composed of 6 population-based cohorts from 3 continents,18–23 but our results might not be generally applicable, in particular to Africans of black ancestry or African Americans. For this reason, we are presently collecting outcome results in additional cohorts, although to our knowledge no prospective population data are available in black subjects.35–37 Second, the 6 populations differed in anthropometric characteristics and lifestyle, and conventional heart rate was only available in 82.9% of our studied 1942 hypertensive patients enrolled in the Progetto Ipertensione Umbria Monitoraggio Ambulatoriale. The 24-hour heart rate was unrelated to total mortality or combined fatal and nonfatal cardiovascular events. However, in analyses adjusted for blood pressure and other risk factors, each 10% decrease in the nocturnal slowing of heart rate was associated with higher total mortality (hazard ratio: 1.30; 95% CI: 1.02 to 1.65) but not with cardiovascular events.2 Ben-Dov et al3 analyzed total mortality in 3957 referred patients across deciles of the awake and asleep heart rate and of the nocturnal decrease in heart rate. He demonstrated that total mortality increased with higher sleeping heart rate (P=0.02) and decreased with more nocturnal fall in heart rate (P<0.001) but was unrelated to the awake heart rate (P=0.50). Two population studies, the Ohasama Study14 and the Pressioni Arteriose Monitorate e Loro Associazioni findings were equally negative for both total and cardiovascular mortality.15 In contrast, home heart rate was a significant predictor of cardiovascular mortality in 1780 Japanese subjects included in the Ohasama Study.34

The present study has potential limitations. First, the IDACO database is currently composed of 6 population-based cohorts from 3 continents,18–23 but our results might not be generally applicable, in particular to Africans of black ancestry or African Americans. For this reason, we are presently collecting outcome results in additional cohorts, although to our knowledge no prospective population data are available in black subjects.35–37 Second, the 6 populations differed in anthropometric characteristics and lifestyle, and conventional heart rate was only available in 82.9% of our

<table>
<thead>
<tr>
<th>Stratification</th>
<th>At Risk, n</th>
<th>Events, n</th>
<th>24-h, Hazard Ratio (95% CI)</th>
<th>Nighttime, Hazard Ratio (95% CI)</th>
<th>Night:Day Ratio, Hazard Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total mortality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All participants</td>
<td>6928</td>
<td>850</td>
<td>1.15 (1.06 to 1.25)‡</td>
<td>1.20 (1.11 to 1.30)‡</td>
<td>1.14 (1.05 to 1.23)‡</td>
</tr>
<tr>
<td>&lt;60 y</td>
<td>3636</td>
<td>113</td>
<td>1.20 (0.96 to 1.49)‡</td>
<td>1.41 (1.15 to 1.72)‡</td>
<td>1.39 (1.15 to 1.65)‡</td>
</tr>
<tr>
<td>≥60 y</td>
<td>3292</td>
<td>737</td>
<td>1.14 (1.05 to 1.24)‡</td>
<td>1.17 (1.07 to 1.28)‡</td>
<td>1.09 (1.00 to 1.19)*</td>
</tr>
<tr>
<td>Normotensive</td>
<td>4434</td>
<td>397</td>
<td>1.17 (1.03 to 1.32)†</td>
<td>1.28 (1.13 to 1.44)†</td>
<td>1.25 (1.11 to 1.40)†</td>
</tr>
<tr>
<td>Hypertensive</td>
<td>2494</td>
<td>453</td>
<td>1.15 (1.03 to 1.28)‡</td>
<td>1.15 (1.03 to 1.29)†</td>
<td>1.05 (0.94 to 1.16)</td>
</tr>
<tr>
<td>Noncardiovascular mortality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All participants</td>
<td>6928</td>
<td>493</td>
<td>1.18 (1.06 to 1.31)‡</td>
<td>1.22 (1.10 to 1.35)‡</td>
<td>1.12 (1.01 to 1.24)*</td>
</tr>
<tr>
<td>Women</td>
<td>3219</td>
<td>139</td>
<td>0.98 (0.80 to 1.20)‡</td>
<td>1.08 (0.89 to 1.32)</td>
<td>1.08 (0.96 to 1.23)</td>
</tr>
<tr>
<td>Men</td>
<td>3709</td>
<td>354</td>
<td>1.27 (1.12 to 1.44)‡</td>
<td>1.29 (1.14 to 1.46)‡</td>
<td>1.24 (1.02 to 1.50)*</td>
</tr>
<tr>
<td>&lt;60 y</td>
<td>3636</td>
<td>74</td>
<td>1.20 (0.92 to 1.58)</td>
<td>1.40 (1.09 to 1.79)</td>
<td>1.36 (1.09 to 1.70)‡</td>
</tr>
<tr>
<td>≥60 y</td>
<td>3292</td>
<td>419</td>
<td>1.17 (1.04 to 1.32)‡</td>
<td>1.18 (1.05 to 1.33)†</td>
<td>1.06 (0.94 to 1.20)</td>
</tr>
</tbody>
</table>

Hypertension was a conventional blood pressure of ≥140 mm Hg systolic or 90 mm Hg diastolic or the use of antihypertensive drugs. All of the hazard ratios were stratified by cohort and adjusted for age, systolic blood pressure measured over the same interval as heart rate, body mass index, smoking and drinking, serum total cholesterol, history of cardiovascular disease, diabetes mellitus, and treatment with antihypertensive drugs. The analyses of the night/day ratio of heart rate were additionally adjusted for night/day ratio of systolic blood pressure. Braces point to heterogeneity between subgroups (P value given).

Significance of the hazard ratios: *P<0.05, †P<0.01, and ‡P<0.001.

Downloaded from hyper.ahajournals.org by JAN STAESSEN on July 24, 2008
study population. Sensitivity analyses showed that no single cohort had a disproportionately large influence. Moreover, a very recent analysis of the Ohasama cohort with follow-up of mortality extended to a median of 12 years (296 deaths) confirmed that, even in the long run, higher nighttime heart rate predicted total mortality. Third, we and most other investigators did not adjust for important determinants of heart rate, such as hemoglobin concentration, hematocrit, or usual physical activity. In particular, low hemoglobin is an index of poor health, is associated with a higher heart rate, and might be a forerunner of imminent cardiovascular or noncardiovascular events. However, our results remained consistent if we excluded patients with an event within 2 years of enrollment. Smoking and drinking alcohol influence heart rate, but our findings were consistent across these strata. Finally, observational data, even if prospective, only allow us to speculate why heart rate is a predictor of total and noncardiovascular mortality. The night:day ratios of heart rate and blood pressure are associated. We demonstrated previously that reverse causality might explain why less nocturnal blood pressure dipping might predict outcome. Subjects in bad health with low mobility are more likely to have an attenuated diurnal rhythm of both blood pressure and heart rate.

Within the limitations of our study, our current findings challenge the commonly held point of view, echoed in recent hypertension guidelines, that heart rate must be a predictor of cardiovascular complications. The 2007 guideline of the Joint National Committee guideline, version 7, stated that heart rate is a risk factor because of the growing body of evidence that higher heart rate might be related to cardiovascular morbidity and mortality, as well as to all-cause mortality. The 3 references to substantiate this recommendation included studies with null findings on the association of heart rate with cardiovascular mortality and no study with positive findings for the association with cardiovascular morbidity. In fact, only the Atherosclerosis Risk in Communities studies demonstrated a positive association between coronary heart disease and office heart rate but only limited to women in analyses without adjustment for blood pressure. The Joint National Committee guideline, version 7, stated that data from epidemiological studies and clinical trials have demonstrated that elevations in resting heart rate and reduced heart rate variability were associated with higher cardiovascular risk. This statement was mainly based on the Framingham Heart Study, in which an average resting heart rate of 83 bpm, according to the expert committee, was associated with a substantially higher risk of cardiovascular morbidity. However, Kannel et al reported that there was a substantial excess of noncardiovascular deaths at higher heart rates but that the proportion of cardiovascular deaths did not increase with heart rate.

**Perspectives**

In the general population, heart rate predicts total and noncardiovascular mortality. With the exception of the night:day ratio, heart rate does not significantly add to the risk stratification for fatal combined with nonfatal cardiovascular events. Additional studies must clarify to what extent previously published results reflect publication bias, studies with positive results being more likely to be published, or might be influenced by red blood cell volume as a harbinger of events or by the level of usual physical activity. To our knowledge, only the findings from Systolic Hypertension in Europe Trial and the Cardiovascular Occupational Risk Factors Detection in Israeli Industries Study were adjusted for hemoglobin. Only 4 studies accounted for physical activity. Expert committees might have to reassess the evidence on which current hypertension guidelines propose heart rate as a consistent predictor of risk.

**Acknowledgments**

We gratefully acknowledge the expert assistance of Sandra Covens (Studies Coordinating Centre, Leuven, Belgium). The IDACO investigators are listed in the data supplement available online at hyper.ahajournals.org.

**Sources of Funding**

The European Union (grants IC15-CT98-0329-EPOGH, LSHM-CT-2006-037093, and HEALTH-F4-2007-201550), the Fonds voor Wetenschappelijk Onderzoek Vlaanderen (Ministry of the Flemish Community, Brussels, Belgium; grants G.0424.03 and G.0575.06), and the Katholieke Universiteit Leuven (grants OT/00/25 and OT/05/49) gave support to the Studies Coordinating Centre. The Danish Heart Foundation (grant 01-2-9-9A-22914), the Beckett Fonden, and the Lundbeck Fonden supported the studies in Copenhagen. The Bilateral Scientific and Technological Collaboration between China and Flanders, Ministry of the Flemish Community, Brussels (grant BIL02/10), supported the fellowship of Y.L. in Leuven. The Ministries of Education, Culture, Sports, Science, and Technology (grants 15790293, 17790381, 18390192, and 18590587) and of Health, Labour, and Welfare (Health Science Research grants and Medical Technology Evaluation Research grants), Grant-in-Aid from the Japanese Society for the Promotion of Science (16.54041 and 18.54042), the Japanese Atherosclerosis Prevention Fund, the Uehara Memorial Foundation, and the Takeda Medical Research Foundation supported research in Japan. The National Natural Science Foundation of China (grant 30571607), Beijing, China, and the Shanghai Commissions of Science and Technology (the “Rising Star” program O6QA14043) and Education (the “Dawn” project) supported the JingNing study in China.

**Disclosures**

None.

**References**


